Biolectrics, a Cleveland, OH-based dental device startup, raised nearly $1m in Series A funding.
The company intends to use the funds to commercialize its OraFlow®.
Led by CEO Steve Cornelius, Biolectrics provides a pain-free, at-home treatment device, OraFlow®, designed to aide dentists in combatting periodontal disease.
The OraFlow is a patented dental device similar in form to an athletic mouth guard and attached to an electronic controller via a cord to provide tiny, painless electrical stimulation to non-invasively kill bacteria associated with periodontal disease. While the exact treatment would be prescribed by a dentist, a typical treatment would last twenty minutes per day for a few months.
Biolectrics has conducted a pilot clinical test on the OraFlow’s safety and effectiveness at the Center for Clinical Dental Studies at the University at Buffalo.A pivotal clinical study is scheduled to commence later this year. Data from this new study will be used to submit to the US FDA for marketing clearance as early as late 2016.